$5.34
7.21% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US63009J1079
Symbol
NBTX
Sector
Industry

Nanobiotix - ADR Stock price

$5.34
+1.58 42.14% 1M
+2.01 60.50% 6M
+2.47 86.22% YTD
-0.01 0.10% 1Y
-8.16 60.41% 5Y
-8.16 60.41% 10Y
-8.16 60.41% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.42 7.21%
ISIN
US63009J1079
Symbol
NBTX
Sector
Industry

Key metrics

Market capitalization $244.36m
Enterprise Value $243.45m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales -18.10
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -138.62%
Revenue (TTM) Revenue $-13.41m
EBIT (operating result TTM) EBIT $-78.99m
Free Cash Flow (TTM) Free Cash Flow $-23.56m
Cash position $57.44m
EPS (TTM) EPS $-1.66
P/E forward negative
P/S forward 12.08
EV/Sales forward 12.03
Short interest 0.02%
Show more

Is Nanobiotix - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Nanobiotix - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Nanobiotix - ADR forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Nanobiotix - ADR forecast:

Buy
90%
Hold
10%

Financial data from Nanobiotix - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
-13 -13
139% 139%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
7% 7%
-
- Research and Development Expense 46 46
6% 6%
-
-77 -77
166% 166%
-
- Depreciation and Amortization 1.87 1.87
4% 4%
-
EBIT (Operating Income) EBIT -79 -79
155% 155%
-
Net Profit -79 -79
72% 72%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nanobiotix - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nanobiotix - ADR Stock News

Neutral
GlobeNewsWire
17 days ago
PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:
Neutral
GlobeNewsWire
23 days ago
PARIS and CAMBRIDGE, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today provided an update on operational progress and reported financial results for the first quarter of 2025.
Neutral
GlobeNewsWire
about one month ago
PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:
More Nanobiotix - ADR News

Company Profile

Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. It also engages in the development of magnetic particles and laser activated nanoparticles for the treatment and diagnosis of cancer. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

Head office France
CEO Laurent Lévy
Employees 108
Founded 2003
Website www.nanobiotix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today